Leveraging BTK Inhibitors in Chronic Lymphocytic Leukemia
June 26th 2023
The choice of BTK inhibitor regimen for patients with chronic lymphocytic leukemia must be tailored to the patient, taking into consideration their preferences and comorbidities, as well as potential treatment-related adverse effects.